This CPB has been updated (i) to state that Eligard (leuprolide acetate), Firmagon (degarelix), Lupron Depot (leuprolide acetate for depot suspension), and Trelstar (triptorelin) will be added to the National Precertification List effective September 1, 2020. This CPB revises existing criteria for the drugs that are considered medically necessary for pubertal suppression in gender dysphoria, to state that the member has reached Tanner stage 2 of puberty or greater (previously stated Tanner Stage 2 of puberty).